SLC5A2 and diabetic kidney disease: 4.Current standard-of-care, including angiotensin-converting enzyme inhibitor, angiotensin II receptor blockers, and sodium-glucose cotransporter 2 inhibitor, does not seem to reduce the inflammation-associated risk in DKD (Figure 4e and f).